欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2024, Vol. 29 ›› Issue (2): 230-235.doi: 10.12092/j.issn.1009-2501.2024.02.013

• 综述与讲座 • 上一篇    下一篇

孕激素治疗子宫内膜癌研究进展

张立仪,郭紫芬   

  1. 南华大学衡阳医学院药学院药物药理研究所,衡阳  421001,湖南
  • 收稿日期:2023-07-10 修回日期:2023-11-10 出版日期:2024-02-26 发布日期:2024-02-02
  • 通讯作者: 郭紫芬,女,博士,教授,研究方向:基因诊断与个体化用药。 E-mail:guozifen@aliyun.com
  • 作者简介:张立仪,女,研究方向:基因诊断与个体化用药。 E-mail:2744223066@qq.com
  • 基金资助:
    湖南省教育厅重点项目(19A419);湖南省大学生创新创业训练计划项目(S202210555285)

Research advance in progesterone therapy for endometrial cancer

ZHANG Liyi, GUO Zifen   

  1. Institute of Pharmacy and Pharmacology, School of Pharmaceutical Science, Hengyang Medical College, University of South China, Hengyang 421001, Hunan, China
  • Received:2023-07-10 Revised:2023-11-10 Online:2024-02-26 Published:2024-02-02

摘要:

子宫内膜癌原发于子宫内膜,是常见的妇科恶性肿瘤之一,其发病率及死亡率仍在逐年上升。虽然子宫内膜癌多见于围绝经期和绝经后女性,但近年来该病有着明显的年轻化趋势。对于未生育但有生育意愿的年轻患者,应用孕激素治疗子宫内膜癌近年来在临床上取得了很大的进展。鉴于孕激素临床应用个体差异大、作用机制不明确等问题,本文就孕激素的临床应用现状、疗效、孕激素抵抗及其机制进行综述。

关键词: 孕激素, 子宫内膜癌, 临床应用, 孕激素抵抗

Abstract:

Endometrial cancer originates from the endometrium and is one of the common gynecologic malignancies, with its incidence and mortality rate increasing year by year. Although endometrial cancer is more prevalent in the peri- and post-menopausal female population, it has been an evident trend in recent years towards younger patients. For young patients who have not yet given birth but intend to do so, the application of progestins in endometrial cancer treatment has made significant progress in clinical practice. Considering the existence of large individual differences and unclear mechanisms of action in the clinical application of progestins, this paper aims to provide an overview of the current clinical application status, efficacy, hormone resistance, and its mechanisms in the context of hormone therapy.

Key words: progesterone, endometrial cancer, clinical application, progesterone resistance

中图分类号: